| [1] |
Coiffier B, Thieblemont C, Van Den Neste E, et al.
Long-term outcome of patients in the LNH-98.5 trial, the first randomized study comparing rituximab-CHOP to standard CHOP chemotherapy in DLBCL patients: a study by the Groupe d'Etudes des Lymphomes de l'Adulte[J]. BloodBlood, 2010, 116(12): 2040-2045.
doi: 10.1182/blood-2010-03-276246 |
| [2] |
Coleman M, Lammers PE, Ciceri F, Jacobs IA, et al.
Role of Rituximab and Rituximab Biosimilars in Diffuse Large B-Cell Lymphoma[J]. Clin Lymphoma Myeloma LeukClin Lymphoma Myeloma Leuk, 2016, 16(4): 175-181.
doi: 10.1016/j.clml.2016.01.004 |
| [3] |
Pfreundschuh M, Kuhnt E, Trümper L.
CHOP-like chemotherapy with or without rituximab in young patients with good-prognosis diffuse large-B-cell lymphoma: 6-year results of an open-label randomised study of the MabThera International Trial (MInT) Group[J]. Lancet OncolLancet Oncol, 2011, 12(11): 1013-1022.
doi: 10.1016/S1470-2045(11)70235-2 |
| [4] |
周剑峰, 黄伟.
弥漫大B细胞淋巴瘤的预后及分层治疗[J]. 临床内科杂志临床内科杂志, 2015, 32(3): 159-162.
doi: 10.3969/j.issn.1001-9057.2015.03.004 Zhou JF, Huang W. Prognosis and stratified treatment of diffuse large B cell lymphoma[J]. J Clin Intern MedJ Clin Intern Med, 2015, 32(3): 159-162. doi: 10.3969/j.issn.1001-9057.2015.03.004 |
| [5] |
Ziepert M, Hasenclever D, Kuhnt E, et al.
Standard International Prognostic Index Remains a Valid Predictor of Outcome for Patients With Aggressive CD20+ B-Cell Lymphoma in the Rituximab Era[J]. J Clin OncolJ Clin Oncol, 2010, 28(14): 2373-2380.
doi: 10.1200/jco.2009.26.2493 |
| [6] |
宋佳琳, 魏小磊, 张元坤, 等.
IPI、NCCN-IPI及年龄调整的IPI评分系统在弥漫大B细胞淋巴瘤患者中的预后价值比较[J]. 中华血液学杂志中华血液学杂志, 2018, 39(9): 739-744.
doi: 10.3760/cma.j.issn.0253-2727.2018.09.007 Song JL, Wei XL, Zhang YK, et al. The prognostic value of the international prognostic index, the national comprehensive cancer network IPI and the age-adjusted IPI in diffuse large B cell lymphoma[J]. Chin J HematolChin J Hematol, 2018, 39(9): 739-744. doi: 10.3760/cma.j.issn.0253-2727.2018.09.007 |
| [7] |
Stiff PJ, Unger JM, Cook JR, et al.
Autologous Transplantation as Consolidation for Aggressive Non-Hodgkin's Lymphoma[J]. N Engl J MedN Engl J Med, 2013, 369(18): 1681-1690.
doi: 10.1056/NEJMoa1301077 |
| [8] |
Ott G, Ziepert M, Klapper W, et al.
Immunoblastic morphology but not the immunohistochemical GCB/nonGCB classifier predicts outcome in diffuse large B-cell lymphoma in the RICOVER-60 trial of the DSHNHL[J]. BloodBlood, 2010, 116(23): 4916-4925.
doi: 10.1182/blood-2010-03-276766 |
| [9] |
Rosenwald A, Wright G, Chan WC, et al.
The Use of Molecular Profiling to Predict Survival After Chemotherapy for Diffuse Large-B-Cell Lymphoma[J]. N Engl J MedN Engl J Med, 2002, 346(25): 1937-1947.
doi: 10.1056/NEJMoa012914 |
| [10] |
Campo E, Swerdlow SH, Harris NL, et al.
The 2008 WHO classification of lymphoid neoplasms and beyond: evolving concepts and practical applications[J]. BloodBlood, 2011, 117(19): 5019-5032.
doi: 10.1182/blood-2011-01-293050 |
| [11] |
Bouabdallah R, Mounier N, Guettier C, et al.
T-Cell/Histiocyte-Rich Large B-Cell Lymphomas and Classical Diffuse Large B-Cell Lymphomas Have Similar Outcome After Chemotherapy: A Matched-Control Analysis[J]. J Clin OncolJ Clin Oncol, 2003, 21(7): 1271-1277.
doi: 10.1200/JCO.2003.06.046 |
| [12] |
Aki H, Tuzuner N, Ongoren S, et al.
T-cell-rich B-cell lymphoma: a clinicopathologic study of 21 cases and comparison with 43 cases of diffuse large B-cell lymphoma[J]. Leuk ResLeuk Res, 2004, 28(3): 229-236.
doi: 10.1016/S0145-2126(03)00253-4 |
| [13] |
Castillo JJ, Bibas M, Miranda RN.
The biology and treatment of plasmablastic lymphoma[J]. BloodBlood, 2015, 125(15): 2323-2330.
doi: 10.1182/blood-2014-10-567479 |
| [14] |
Lenz G, Staudt LM.
Aggressive lymphomas[J]. N Engl J MedN Engl J Med, 2010, 362(15): 1417-1429.
doi: 10.1056/NEJMra0807082 |
| [15] |
Alizadeh AA, Eisen MB, Davis RE, et al.
Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling[J]. NatureNature, 2000, 403(6769): 503-511.
doi: 10.1038/35000501 |
| [16] |
Hans CP, Weisenburger DD, Greiner TC, et al.
Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray[J]. BloodBlood, 2004, 103(1): 275-282.
doi: 10.1182/blood-2003-05-1545 |
| [17] |
Thieblemont C, Briere J, Mounier N, et al.
The Germinal Center/Activated B-Cell Subclassification Has a Prognostic Impact for Response to Salvage Therapy in Relapsed/Refractory Diffuse Large B-Cell Lymphoma: A Bio-CORAL Study[J]. J Clin OncolJ Clin Oncol, 2011, 29(31): 4079-4087.
doi: 10.1200/jco.2011.35.4423 |
| [18] |
Scott DW, Wright GW, Williams PM, et al.
Determining cell-of-origin subtypes of diffuse large B-cell lymphoma using gene expression in formalin-fixed paraffin-embedded tissue[J]. BloodBlood, 2014, 123(8): 1214-1217.
doi: 10.1182/blood-2013-11-536433 |
| [19] |
Scott DW, Mottok A, Ennishi D, et al.
Prognostic Significance of Diffuse Large B-Cell Lymphoma Cell of Origin Determined by Digital Gene Expression in Formalin-Fixed Paraffin-Embedded Tissue Biopsies[J]. J Clin OncolJ Clin Oncol, 2015, 33(26): 2848-2856.
doi: 10.1200/JCO.2014.60.2383 |
| [20] |
Savage KJ, Johnson NA, Ben-Neriah S, et al.
MYC gene rearrangements are associated with a poor prognosis in diffuse large B-cell lymphoma patients treated with R-CHOP chemotherapy[J]. BloodBlood, 2009, 114(17): 3533-3537.
doi: 10.1182/blood-2009-05-220095 |
| [21] |
Barrans S, Crouch S, Smith A, et al.
Rearrangement of MYC Is Associated With Poor Prognosis in Patients With Diffuse Large B-Cell Lymphoma Treated in the Era of Rituximab[J]. J Clin OncolJ Clin Oncol, 2010, 28(20): 3360-3365.
doi: 10.1200/JCO.2009.26.3947 |
| [22] |
Petrich AM, Nabhan C, Smith SM.
MYC-associated and double-hit lymphomas: A review of pathobiology, prognosis, and therapeutic approaches[J]. CancerCancer, 2014, 120(24): 3884-3895.
doi: 10.1002/cncr.28899 |
| [23] |
Hu SM, Xu-Monette ZY, Tzankov A, et al.
MYC/BCL2 protein coexpression contributes to the inferior survival of activated B-cell subtype of diffuse large B-cell lymphoma and demonstrates high-risk gene expression signatures: a report from The International DLBCL Rituximab-CHOP Consortium Program[J]. BloodBlood, 2013, 121(20): 4021-4031.
doi: 10.1182/blood-2012-10-460063 |
| [24] |
Oki Y, Noorani M, Lin P, et al.
Double hit lymphoma: the MD Anderson Cancer Center clinical experience[J]. Br J HaematolBr J Haematol, 2014, 166(6): 891-901.
doi: 10.1111/bjh.12982 |
| [25] |
Landsburg DJ, Petrich AM, Abramson JS, et al.
Impact of oncogene rearrangement patterns on outcomes in patients with double-hit non-Hodgkin lymphoma[J]. CancerCancer, 2016, 122(4): 559-564.
doi: 10.1002/cncr.29781 |
| [26] |
Landsburg DJ, Falkiewicz MK, Petrich AM, et al.
Sole rearrangement but not amplification of MYC is associated with a poor prognosis in patients with diffuse large B cell lymphoma and B cell lymphoma unclassifiable[J]. Br J HaematolBr J Haematol, 2016, 175(4): 631-640.
doi: 10.1111/bjh.14282 |
| [27] |
Li WH, Tang Y, Song YC, et al.
Prognostic Role of Pretreatment Plasma D-Dimer in Patients with Solid Tumors: a Systematic Review and Meta-Analysis[J]. Cell Physiol BiochemCell Physiol Biochem, 2018, 45(4): 1663-1676.
doi: 10.1159/000487734 |
| [28] |
Mu SD, Ai LS, Fan FJ, et al. Prognostic role of neutrophil-to-lymphocyte ratio in diffuse large B cell lymphoma patients: an updated dose-response meta-analysis[J/OL]. Cancer Cell Int, 2018, 18: 119[2019-02-21]. https://cancerci.biomedcentral.com/articles/10.1186/s12935-018-0609-9. DOI: 10.1186/s12935−018−0609−9. |
| [29] |
Sasanelli M, Meignan M, Haioun C, et al.
Pretherapy metabolic tumour volume is an independent predictor of outcome in patients with diffuse large B-cell lymphoma[J]. Eur J Nucl Med Mol ImagingEur J Nucl Med Mol Imaging, 2014, 41(11): 2017-2022.
doi: 10.1007/s00259-014-2822-7 |
| [30] |
梁颖, 吴宁, 方艳, 等.
18F-FDG PET/CT显像SUVmax、MTV和TLG判断弥漫性大B细胞淋巴瘤的预后价值[J]. 中华核医学与分子影像杂志中华核医学与分子影像杂志, 2015, 35(2): 97-101.
doi: 10.3760/cma.j.issn.2095-2848.2015.02.005 Liang Y, Wu N, Fang Y, et al. Prognostic significance of SUVmax, MTV and TLG on 18F-FDG PET/CT imaging in patients with diffuse large B-cell lymphoma[J]. Chin J Nucl Med Mol ImagingChin J Nucl Med Mol Imaging, 2015, 35(2): 97-101. doi: 10.3760/cma.j.issn.2095-2848.2015.02.005 |
| [31] |
丁重阳, 郭喆, 孙晋, 等.
治疗前18F-FDG PET-CT显像预测中晚期弥漫大B细胞淋巴瘤预后的价值[J]. 中华肿瘤杂志中华肿瘤杂志, 2018, 40(7): 528-533.
doi: 10.3760/cma.j.issn.0253-3766.2018.07.009 Ding CY, Guo Z, Sun J, et al. Prognostic value of pretreatment 18F-FDG PET-CT for patients with advanced diffuse large B-cell lymphoma[J]. Chin J OncolChin J Oncol, 2018, 40(7): 528-533. doi: 10.3760/cma.j.issn.0253-3766.2018.07.009 |
| [32] |
应志涛, 王雪鹃, 宋玉琴, 等.
治疗前18F-FDG PET/CT最大标准摄取值在弥漫大B细胞淋巴瘤中的意义[J]. 中华医学杂志中华医学杂志, 2012, 92(46): 3246-3249.
doi: 10.3760/cma.j.issn.0376-2491.2012.46.003 Ying ZT, Wang XJ, Song YQ, et al. Prognostic value of maximum standard uptake on pretreatment 18F-FDG PET/CT scan in newly diagnosed diffuse large B cell lymphoma[J]. Natl Med J ChinaNatl Med J China, 2012, 92(46): 3246-3249. doi: 10.3760/cma.j.issn.0376-2491.2012.46.003 |
| [33] |
Decazes P, Becker S, Toledano MN, et al.
Tumor fragmentation estimated by volume surface ratio of tumors measured on 18F-FDG PET/CT is an independent prognostic factor of diffuse large B-cell lymphoma[J]. Eur J Nucl Med Mol ImagingEur J Nucl Med Mol Imaging, 2018, 45(10): 1672-1679.
doi: 10.1007/s00259-018-4041-0 |
| [34] |
Evens AM, Kostakoglu L.
The role of FDG-PET in defining prognosis of Hodgkin lymphoma for early-stage disease[J]. BloodBlood, 2014, 124(23): 3356-3364.
doi: 10.1182/blood-2014-05-577627 |
| [35] |
Barrington SF, Mikhaeel NG, Kostakoglu L, et al.
Role of Imaging in the Staging and Response Assessment of Lymphoma: Consensus of the International Conference on Malignant Lymphomas Imaging Working Group[J]. J Clin OncolJ Clin Oncol, 2014, 32(27): 3048-3058.
doi: 10.1200/JCO.2013.53.5229 |
| [36] |
Haioun C, Itti E, Rahmouni A, et al.
[18F]fluoro-2-deoxy-d-glucose positron emission tomography (FDG-PET) in aggressive lymphoma: an early prognostic tool for predicting patient outcome[J]. BloodBlood, 2005, 106(4): 1376-1381.
doi: 10.1182/blood-2005-01-0272 |
| [37] |
Safar V, Dupuis J, Itti E, et al.
Interim [18F]Fluorodeoxyglucose Positron Emission Tomography Scan in Diffuse Large B-Cell Lymphoma Treated With Anthracycline-Based Chemotherapy Plus Rituximab[J]. J Clin OncolJ Clin Oncol, 2012, 30(2): 184-190.
doi: 10.1200/JCO.2011.38.2648 |
| [38] |
江茂情, 陈萍, 阮新忠, 等.
化疗中期18F-FDG PET/CT显像对弥漫性大B细胞淋巴瘤的预后评估效能[J]. 中华核医学与分子影像杂志中华核医学与分子影像杂志, 2018, 38(6): 395-398.
doi: 10.3760/cma.j.issn.2095-2848.2018.06.004 Jiang MQ, Chen P, Ruan XZ, et al. Prognostic efficiency of interim 18F-FDG PET/CT in patients with diffuse large B-cell lymphoma[J]. Chin J Nucl Med Mol ImagingChin J Nucl Med Mol Imaging, 2018, 38(6): 395-398. doi: 10.3760/cma.j.issn.2095-2848.2018.06.004 |
| [39] |
Cashen AF, Dehdashti F, Luo JQ, et al.
18F-FDG PET/CT for Early Response Assessment in Diffuse Large B-Cell Lymphoma: Poor Predictive Value of International Harmonization Project Interpretation[J]. J Nucl MedJ Nucl Med, 2011, 52(3): 386-392.
doi: 10.2967/jnumed.110.082586 |
| [40] |
Mamot C, Klingbiel D, Hitz F, et al.
Final Results of a Prospective Evaluation of the Predictive Value of Interim Positron Emission Tomography in Patients With Diffuse Large B-Cell Lymphoma Treated With R-CHOP-14 (SAKK 38/07)[J]. J Clin OncolJ Clin Oncol, 2015, 33(23): 2523-2529.
doi: 10.1200/JCO.2014.58.9846 |
| [41] |
朱璐婷, 岑溪南, 欧晋平, 等.
中期18F-FDG PET/CT显像不同评价方法对弥漫大B细胞淋巴瘤患者预后判断价值[J]. 中国实验血液学杂志中国实验血液学杂志, 2017, 25(2): 431-437.
doi: 10.7534/j.issn.1009-2137.2017.02.022 Zhu LT, Cen XN, Ou JP, et al. Values of Different Evaluation Criteria of Interim 18F-FDG PET/CT Scan for Prediction of Prognosis in Patients with DLBCL[J]. J Exp HematolJ Exp Hematol, 2017, 25(2): 431-437. doi: 10.7534/j.issn.1009-2137.2017.02.022 |
| [42] |
高艳, 赵晋华, 宋建华, 等.
ΔSUV法和Deauville五分法在弥漫性大B细胞淋巴瘤预后中的作用[J]. 中华核医学与分子影像杂志中华核医学与分子影像杂志, 2016, 36(5): 420-425.
doi: 10.3760/cma.j.issn.2095-2848.2016.05.009 Gao Y, Zhao JH, Song JH, et al. Prognostic value of △SUV and Deauville 5-point scoring in patients with diffuse large B-cell lymphoma[J]. Chin J Nucl Med Mol ImagingChin J Nucl Med Mol Imaging, 2016, 36(5): 420-425. doi: 10.3760/cma.j.issn.2095-2848.2016.05.009 |
| [43] |
Moskowitz CH, Schöder H, Teruya-Feldstein J, et al.
Risk-Adapted Dose-Dense Immunochemotherapy Determined by Interim FDG-PET in Advanced-Stage Diffuse Large B-Cell Lymphoma[J]. J Clin OncolJ Clin Oncol, 2010, 28(11): 1896-1903.
doi: 10.1200/JCO.2009.26.5942 |
| [44] |
Swinnen LJ, Li HL, Quon A, et al.
Response-adapted therapy for aggressive non-Hodgkin's lymphomas based on early [18F] FDG-PET scanning: ECOG-ACRIN Cancer Research Group study (E3404)[J]. Br J HaematolBr J Haematol, 2015, 170(1): 56-65.
doi: 10.1111/bjh.13389 |
| [45] |
Burggraaff CN, Cornelisse AC, Hoekstra OS, et al.
Interobserver Agreement of Interim and End-of-Treatment 18F-FDG PET/CT in Diffuse Large B-Cell Lymphoma: Impact on Clinical Practice and Trials[J]. J Nucl MedJ Nucl Med, 2018, 59(12): 1831-1836.
doi: 10.2967/jnumed.118.210807 |
| [46] |
Meignan M, Gallamini A, Meignan M, et al.
Report on the First International Workshop on interim-PET scan in lymphoma[J]. Leuk lymphomaLeuk lymphoma, 2009, 50(8): 1257-1260.
doi: 10.1080/10428190903040048 |
| [47] |
Nols N, Mounier N, Bouazza S, et al.
Quantitative and qualitative analysis of metabolic response at interim positron emission tomography scan combined with International Prognostic Index is highly predictive of outcome in diffuse large B-cell lymphoma[J]. Leuk LymphomaLeuk Lymphoma, 2014, 55(4): 773-780.
doi: 10.3109/10428194.2013.831848 |
| [48] |
Yoo C, Lee DH, Kim JE, et al.
Limited role of interim PET/CT in patients with diffuse large B-cell lymphoma treated with R-CHOP[J]. Ann HematolAnn Hematol, 2011, 90(7): 797-802.
doi: 10.1007/s00277-010-1135-6 |
| [49] |
Hong J, Kim JH, Lee KH, et al.
Symptom-oriented clinical detection versus routine imaging as a monitoring policy of relapse in patients with diffuse large B-cell lymphoma[J]. Leuk LymphomaLeuk Lymphoma, 2014, 55(10): 2312-2318.
doi: 10.3109/10428194.2014.882505 |
| [50] |
Bolshinsky M, Nabhan C.
Interim PET Scans in Diffuse Large B-Cell Lymphoma: Is It Ready for Prime Time?[J]. Clin Lymphoma Myeloma LeukClin Lymphoma Myeloma Leuk, 2016, 16(12): 655-661.
doi: 10.1016/j.clml.2016.08.020 |